Amy K. Barone

Pediatrics | Hematology | Oncology

8081 Innovation Park Dr
765
Fairfax, VA 22031

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Evaluating "Brain Permeability": A Critical Issue for the Development of Therapeutic Agents for Primary and Metastatic Brain Tumors.

Evaluating "Brain Permeability": A Critical Issue for the Development of Therapeutic Agents for Primary and Metastatic Brain Tumors.

Journal: Neuro-oncology

Published: November 26, 2025

Evaluating "brain permeability": A critical issue for the development of therapeutic agents for primary and metastatic brain tumors.

Evaluating "brain permeability": A critical issue for the development of therapeutic agents for primary and metastatic brain tumors.

Journal: Neuro-oncology

Published: November 26, 2025

FDA Approval Summary: Tarlatamab for the Treatment of Extensive-Stage Small Cell Lung Cancer.

FDA Approval Summary: Tarlatamab for the Treatment of Extensive-Stage Small Cell Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 28, 2025

FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.

FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 11, 2025

Use of External Control Cohorts in Pediatric Brain Tumor Clinical Trials.

Use of External Control Cohorts in Pediatric Brain Tumor Clinical Trials.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 23, 2024

Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 14, 2022

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 18, 2022

Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.

Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 08, 2021

US Food and Drug Administration regulatory updates in neuro-oncology.

US Food and Drug Administration regulatory updates in neuro-oncology.

Journal: Journal of neuro-oncology

Published: May 10, 2021

Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience.

Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience.

Journal: Neuro-oncology

Published: April 06, 2021

Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials.

Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials.

Journal: Neuro-oncology

Published: November 01, 2020

Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 14, 2020

Showing 1-12 of 21

Last Updated: 09/26/2026